Journal article
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- Abstract:
-
Background: Available therapies for myelofibrosis may exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. The JAK2/FLT3 inhibitor pacritinib induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pacritinib vs best available therapy in patients with myelofibrosis irrespective of baseline cytopenias.
Expand abstract
Methods: In the international phase 3 PERSIST-1 trial, patients with higher-risk m...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 2.0MB)
-
- Publisher copy:
- 10.1016/S2352-3026(17)30027-3
Authors
Funding
CTI BioPharma Corp
More from this funder
Bibliographic Details
- Publisher:
- Lancet Publisher's website
- Journal:
- Lancet Haematology Journal website
- Volume:
- 4
- Issue:
- 5
- Pages:
- e225-e236
- Publication date:
- 2017-03-20
- Acceptance date:
- 2017-01-01
- DOI:
- EISSN:
-
2352-3026
- ISSN:
-
2352-3026
Item Description
- Keywords:
- Pubs id:
-
pubs:689111
- UUID:
-
uuid:6d22126f-0b16-47f8-a7b2-fda7a1781c22
- Local pid:
- pubs:689111
- Source identifiers:
-
689111
- Deposit date:
- 2017-05-05
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2017
- Notes:
- © 2017 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: [10.1016/S2352-3026(17)30027-3].
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record